Lactobacillus rhamnosus – LR05 (DSM 19739)

    Immunology blend | Immune stimulation

    • Lactobacillus rhamnosus – LR04 (DSM 16605)
    • Lactobacillus rhamnosus – LR05 (DSM 19739)
    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus plantarum – LP02 (LMG P-21020)
    • Bifidobacterium animalis subsp. lactis – BS01 (LMG P-21384)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    2.5 billion CFU + 2.5 billion CFU + 2.5 billion CFU + 2.5 billion CFU + 5 billion CFU + FOS or GOS

    FUNCTIONALITY
    Reinforcement of the natural defences • Reduction of the intestinal discomfort • Rebalance of the intestinal microbiota

    Scientific support

    Human clinical trial
    1) Pregliasco F. et al. A New Chance of Preventing Winter Diseases by the Administration of Symbiotic Formulations. Journal of Clinical Gastroenterology, 2008; 42(2): 224-233.
    2) Belcaro G. et al. Prevention of flu episodes with colostrum and Bifivir compared with vaccination: an epidemiological, registry study. Panminerva Medica 2010;52:269-75.

    In vitro study
    Mogna L. et al. Micronized Cells of the Probiotic Strain Bifidobacterium lactis BS01 Activate Monocyte Polarization: A New Approach. J Clin Gastroenterol. 2018;52:S57-S61.

    + Internal data on immune stimulation and anti-pathogen activity available upon request for certain strains


    Dermatology blend | Atopic dermatitis

    • Bifidobacterium animalis subsp. lactis – BS01 (LMG P-21384)
    • Lactobacillus rhamnosus – LR05 (DSM 19739)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    1 billion

    FUNCTIONALITY
    Atopic dermatitis

    Scientific support

    Human clinical trial
    Manzotti G. et al. Probiotics as a Novel Adjuvant Approach to Atopic Dermatitis. Journal of Contemporary Immunology (2014) Vol. 1 No. 2 pp. 57-66.

    + Immunomodulation in vitro data available upon request